Since PLpro enzyme is known to suppress the IFN-α/β mediated anti-viral response though DUB activity and responsible for cytokine storm in COVID-19 patients, use of aloin isoforms as an anti-SARS-CoV-2 drug may promote the IFN-α/β mediated anti-viral response and limit the cytokine storm in COVID-19 patients. The gene discussed is IFNA17; the disease is COVID-19.